The Montpellier, France–based company won expanded indications for Epione in the treatment of lung tumors.
Epione, the company’s flagship product, offers curative treatment for cancers. Quantum Surgical designed it to plan, target, deliver and confirm tumor ablation in a minimally invasive procedure. The percutaneous ablation system uses a robotic arm, a navigation system and a camera.
It enables physicians to treat inoperable, particularly difficult-to-reach tumors at an early stage in a simple and effective way. Epione’s uses include the treatment of abdominal tumors, including in the liver, kidney and pancreas.
Having received FDA 510(k) clearance in March 2022, Epione has treated more than 200 patients in France and the U.S. to date.
Quantum Surgical said the new expanded approval came on the back of a clinical study conducted at Gustave Roussy. Professor Thierry De Baère, an interventional radiologist at Gustave Roussy, coordinated the study. He said Epione demonstrated the ability to consistently enable technical success while remaining safe.
“With Epione, our goal is to provide patients with an effective, better targeted and minimally invasive treatment. While over 2 million new cases of lung cancer diagnosed each year worldwide, we are delighted that our technology can now be accessible to new patients in Europe,” said Bertin Nahum, president and co-founder of Quantum Surgical.
